Is hydroxyzine effective for treating anxiety?

Hydroxyzine for Anxiety

Hydroxyzine is FDA-approved for symptomatic relief of anxiety and tension associated with psychoneurosis, but its effectiveness for long-term use (beyond 4 months) has not been established, and it should not be considered a first-line treatment for generalized anxiety disorder. 1

FDA-Approved Indication with Important Limitations

The FDA label explicitly states that hydroxyzine is indicated for symptomatic relief of anxiety and tension, but critically notes that "the effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies" 1. This is a significant limitation that must guide clinical decision-making.

Evidence Quality and Recommendations

Short-Term Efficacy (4-12 weeks)

Multiple randomized controlled trials demonstrate that hydroxyzine (50 mg/day) is superior to placebo for GAD over 4-12 week periods:

• Efficacy begins within the first week of treatment and is maintained throughout short-term trials 2, 3, 4
• A 3-month study showed mean Hamilton Anxiety Scale improvement of -12.16 points with hydroxyzine versus -9.64 with placebo (p=0.019) 2
• Hydroxyzine performed comparably to benzodiazepines (bromazepam) and buspirone in head-to-head trials 2, 3

Critical Limitations

A 2010 Cochrane systematic review concluded that "due to the high risk of bias of the included studies, the small number of studies and the overall small sample size, it is not possible to recommend hydroxyzine as a reliable first-line treatment in GAD" 5. This represents the highest-quality synthesis of available evidence.

Guideline Context: Not Mentioned in Current Standards

The 2020 AACAP guidelines for anxiety disorders in children and adolescents make no mention of hydroxyzine 6. The guidelines focus on:

• SSRIs as first-line pharmacotherapy
• SNRIs as alternative pharmacotherapy
• Combination CBT plus SSRI for optimal outcomes

This absence from current guidelines is telling—hydroxyzine has been superseded by medications with better-established long-term efficacy and safety profiles.

Adverse Effects Profile

Common side effects include:

• Drowsiness/sleepiness (28% vs 14% with placebo) - typically transient, appearing in the first week 4
• Dry mouth (14% vs 5%)
• Weight gain (12% vs 10%)
• Loss of concentration (9% vs 8%)

The sedation profile may actually be problematic for functional outcomes, despite being tolerable.

Clinical Algorithm for Use

If considering hydroxyzine:

1. Reserve for short-term use only (≤4 months maximum) given lack of long-term data 1
2. Consider only when first-line treatments are contraindicated or refused:
   • SSRIs/SNRIs are preferred first-line agents
   • CBT should be offered when available
3. Dose: 50 mg/day (12.5 mg morning and midday, 25 mg evening) based on trial evidence 2, 3
4. Expect onset within 1 week - if no response by 2 weeks, reconsider the approach 4
5. Monitor for excessive sedation that impairs function
6. Plan discontinuation strategy - studies show no rebound anxiety after abrupt discontinuation 4

Common Pitfalls

• Using hydroxyzine as first-line therapy when SSRIs have superior evidence for long-term efficacy
• Continuing beyond 4 months without reassessing, given the absence of long-term efficacy data 1
• Ignoring the sedation profile in patients who need to maintain alertness for work/school
• Assuming equivalence to benzodiazepines - while comparable in some trials, hydroxyzine lacks the robust evidence base of other anxiolytics

Bottom Line

Hydroxyzine has FDA approval and short-term efficacy data for anxiety, but the evidence base is limited by study quality and duration. Modern treatment algorithms prioritize SSRIs, SNRIs, and CBT over hydroxyzine 6. Hydroxyzine may serve as a short-term adjunct or alternative when standard treatments cannot be used, but should not be the default choice for anxiety management.